Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Darifenacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 3/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 3/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Darifenacin SCHEMBL31257801 | 1.00 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL2774455 | 1.00 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL113331 | 1.00 | CHRM5 (1.00) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL1023445 | 0.99 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL3662174 | 0.99 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL1318587 | 0.99 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL138745 | 0.99 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL5085916 | 0.99 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL453486 | 0.99 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 | |
| Darifenacin SCHEMBL1973347 | 0.99 | CHRM5 (0.98) | CHRM5CHRM1CHRM4CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9244 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-12638459-B2 | Method of diagnosing overactive bladder disorder | UNIVERSITY OF PORTSMOUTH HIGHER EDUCATION CORPORATION (GB) | 2026-05-26 | — | — | US | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | claimed |
| EP-4706766-A2 | TOPICAL OPHTHALMOLOGICAL COMPOSITIONS | ADS Therapeutics LLC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4676445-A1 | MICROSPHERE FORMULATIONS AND METHODS OF PREPARATION THEREOF | Lotus Biopharma Inc. (US) | 2026-01-14 | — | — | EP | claimed |
| US-20250381180-A1 | METHODS OF TREATING OR PREVENTING OVERACTIVE BLADDER SYNDROME | PURDUE PHARMA L.P. (US) | 2025-12-18 | — | — | US | claimed |
| US-12485177-B2 | Topical ophthalmological compositions | ADS THERAPEUTICS LLC (US) | 2025-12-02 | — | — | US | claimed |
| US-5837724-A | Method of enhancing cognition | PFIZER INC. (US) | 1998-11-17 | — | — | US | claimed |
| CN-1195984-A | Pharmaceutical formulations containing darifenacin | PFIZER RES & DEV (IE) | 1998-10-14 | — | — | CN | claimed |
| EP-0850059-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING DARIFENACIN | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-07-01 | — | — | EP | claimed |
| WO-1998011888-A1 | METHOD OF TREATING URINARY INCONTINENCE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-03-26 | — | — | WO | claimed |
| EP-0813870-A1 | Use of darifenacin to enhance cognitive functions | Pfizer Limited (GB) | 1997-12-29 | — | — | EP | claimed |
| WO-1997009980-A1 | PHARMACEUTICAL FORMULATIONS CONTAINING DARIFENACIN | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-03-20 | — | — | WO | claimed |
| WO-1995019164-A1 | USE OF M3 MUSCARINIC ANTAGONISTS FOR THE TREATMENT OF MOTION SICKNESS | PFIZER LIMITED (GB) | 1995-07-20 | — | — | WO | claimed |
| EP-0388054-B1 | Pyrrolidine derivatives | PFIZER LTD (GB) | 1993-11-03 | — | — | EP | claimed |
| US-5096890-A | PYRROLIDINE DERIVATIVES | PFIZER INC. (US) | 1992-03-17 | — | — | US | claimed |
| EP-0388054-A1 | Pyrrolidine derivatives | Pfizer Limited (GB) | 1990-09-19 | — | — | EP | claimed |